Renaissance Capital logo

Conatus Pharmaceuticals Priced, Nasdaq: CNAT

Biotech in Phase 2 trials developing treatments for chronic liver disease.

Industry: Health Care

First Day Return: -13.6%

Biotech in Phase 2 trials developing treatments for chronic liver disease.

Conatus Pharmaceuticals (CNAT) Performance

Created with Highcharts 10.3.2Chart context menuCNAT vs. IPO Index (IPOUSA)2014201520162017201820192020202120222023202420250%+ 200%+ 400%-200%View 5 days5dView 1 month1mView 3 months3mView year to dateYTDView 1 year1yView allAllRenaissance IPO IndexOur ETF tracks the IPO Index